The Epidemiology of the Weiss Cohort Project

Weiss 队列项目的流行病学

• 批准号: 10432011
• 负责人: Stanley H Weiss
• 金额: $ 75.88万
• 依托单位: RBHS-NEW JERSEY MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-15 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10432011
• 关键词: AIDS/HIV problem; ATOD; Accounting; African American; Age; Aging; Agreement; Applications Grants; Authorization documentation; Back; Behavioral; Biological Specimen Banks; Biotechnology; Blood; Caring; Cause of Death; Cessation of life; Cholangiocarcinoma; Chronic; Cohort Studies; Data; Data Set; Death Certificates; Disease; Disease Outcome; Drug Interactions; Drug abuse; Drug usage; Drug user; Enrollment; Epidemic; Epidemiology; Ethnic Origin; European; Evolution; Exposure to; Female; Future; Gender; Genetic; Geography; Goals; Grant; HIV; HIV Seronegativity; Health; Health system plans; Hepatitis C; Hepatitis C virus; Highly Active Antiretroviral Therapy; Hispanic; Human immunodeficiency virus test; Incidence; Individual; Infection; Infectious Agent; Institutes; Intervention; Laboratories; Link; Liver Failure; Liver diseases; Longitudinal Studies; Longterm Follow-up; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Medical; Minority Groups; National Cancer Institute; National Institute of Drug Abuse; Opioid; Outcome; Participant; Pattern; Persons; Pharmaceutical Preparations; Policies; Population; Prevention; Prospective cohort; Race; Recording of previous events; Registries; Relative Risks; Resources; Risk; Risk Factors; Series; Smoking; Source; Stage at Diagnosis; Survival Analysis; Survivors; Time; Treatment Protocols; Underrepresented Minority; Vital Statistics; Woman; Work; adjudicate; burden of illness; cancer epidemiology; cancer risk; cancer site; clinical epidemiology; clinical practice; cohort; data registry; disorder risk; follow-up; high risk; indexing; male; mortality; neoplasm registry; public health intervention; recruit; sex; tool

PROJECT SUMMARY/ABSTRACT The goals of this project are to further our understanding of the long-term clinical epidemiology of health outcomes among drug users who are at high risk for HIV. This is important because it will guide clinical practice and health systems planning in the face of the continuing HIV/AIDS epidemic and the evolving epidemic of drug abuse, including opioids. Many HIV-infected persons are living longer than they had in the past, due to the advent and availability of highly active antiretroviral therapy. We have a unique prospective cohort of drug users established in the 1980s, backed by a linked biospecimen repository and permission for indefinite continuing follow-up, established by the NCI and NIDA for the long- term study of drug users. The cohort numbers nearly 11,000 drug users, who are diverse in gender, race, ethnicity and geography, and include large numbers of both HIV-positive and HIV-negative persons. Hepatitis C virus infection is extremely common in these persons. WE SEEK TO UNDERSTAND THE HEALTH OUTCOMES IN THIS COHORT THROUGH TWO AIMS. AIM 1. To determine the epidemiologic features of mortality outcomes associated with HIV among drug users over a 35-year period. This will be accomplished by matching our cohort to vital statistics registry data. AIM 2. To determine the cancer epidemiology, by cancer site, among drug users over a 35-year period, including incidence, stage at diagnosis, treatment regimens, mortality, and HIV-associated risk. This will be accomplished by matching our cohort to cancer registry data. Our project analyses will integrate these two types of data, with stepwise repetition of matching over several years. Mortality data will enable us to more accurately conduct survival analyses on an array of disease outcomes, with a special focus on cancer to identify putative risk factors. This has the potential to assist with the identification of interventions that would reduce disease burden and prolong survival. We will characterize disease outcomes in HIV-positive compared to HIV-negative drug users, accounting for baseline demographic, behavioral, and medical factors. Our cohort uniquely affords the opportunity to study health outcomes over a prolonged time period spanning several decades in both sexes and in underrepresented minority populations. The size of our study and the extent and richness of baseline data will make it a powerful tool in understanding a wide array of disease outcomes. Given the continuing rapid evolution of biotechnology, future research might employ evolving biotechnology to use our biospecimen repository to explore specific disease outcomes we will be identifying. Our cohort has joined the NIDA Genetics Consortium. We will explore joining other consortia which focus on other outcomes, which could amplify the power of those consortia.

项目摘要/摘要 这个项目的目标是加深我们对健康的长期临床流行病学的理解。 艾滋病毒高危吸毒者的结果。这一点很重要，因为它将指导临床 面对持续的艾滋病毒/艾滋病流行和不断演变的 药物滥用，包括阿片类药物的流行。许多艾滋病毒感染者的寿命比他们在美国时更长 过去，由于高效抗逆转录病毒疗法的出现和可获得性。 我们有一个独特的潜在吸毒者队列，建立在20世纪80年代，由一个相关的生物制品支持 NCI和NIDA建立的长期无限期持续跟踪的储存库和许可- 吸毒者的学期研究。该队列有近11,000名吸毒者，他们在性别、种族、 其中包括大量艾滋病毒阳性者和艾滋病毒阴性者。肝炎 C病毒感染在这些人中非常常见。 我们试图通过两个目标来了解这一队列中的健康结果。 目的1.确定吸毒者中艾滋病毒相关死亡结果的流行病学特征 在35年的时间里。这将通过将我们的队列与生命统计登记册数据相匹配来实现。 目的2.确定35年内吸毒者按癌症部位的癌症流行病学， 包括发病率、诊断阶段、治疗方案、死亡率和艾滋病毒相关风险。这将是 通过将我们的队列与癌症登记数据进行匹配来完成。 我们的项目分析将整合这两种类型的数据，并逐步重复匹配多个 好几年了。死亡率数据将使我们能够更准确地对一系列疾病进行生存分析 结果，特别关注癌症，以确定可能的危险因素。这有可能有助于 确定可减轻疾病负担和延长生存时间的干预措施。 我们将比较艾滋病毒阳性和艾滋病毒阴性吸毒者的疾病结果，说明 基线人口统计、行为和医学因素。我们的同龄人提供了独特的机会来研究 在跨越几十年的较长时间内，两性和 少数族裔人口的代表性不足。 我们研究的规模以及基线数据的范围和丰富程度将使其成为理解 各种各样的疾病后果。鉴于生物技术的持续快速发展，未来的研究可能 利用不断发展的生物技术来使用我们的生物谱系存储库来探索特定的疾病结果，我们将 辨别身份。我们的队列已经加入了NIDA遗传学联盟。我们将探索加入其他财团 它们关注的是其他结果，这可能会放大这些财团的力量。